147,173 Shares in Abeona Therapeutics Inc. (ABEO) Purchased by EAM Investors LLC
EAM Investors LLC bought a new stake in Abeona Therapeutics Inc. (NASDAQ:ABEO) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 147,173 shares of the biopharmaceutical company’s stock, valued at approximately $2,509,000. EAM Investors LLC owned about 0.32% of Abeona Therapeutics as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also modified their holdings of the company. Ardsley Advisory Partners raised its position in shares of Abeona Therapeutics by 33.3% in the second quarter. Ardsley Advisory Partners now owns 60,000 shares of the biopharmaceutical company’s stock valued at $383,000 after buying an additional 15,000 shares during the last quarter. California State Teachers Retirement System acquired a new stake in shares of Abeona Therapeutics in the second quarter valued at about $275,000. State Street Corp acquired a new stake in shares of Abeona Therapeutics in the second quarter valued at about $1,900,000. Vanguard Group Inc. raised its position in shares of Abeona Therapeutics by 11.2% in the second quarter. Vanguard Group Inc. now owns 1,081,670 shares of the biopharmaceutical company’s stock valued at $6,922,000 after buying an additional 108,730 shares during the last quarter. Finally, Northern Trust Corp raised its position in shares of Abeona Therapeutics by 406.3% in the second quarter. Northern Trust Corp now owns 257,668 shares of the biopharmaceutical company’s stock valued at $1,649,000 after buying an additional 206,775 shares during the last quarter. Institutional investors and hedge funds own 36.34% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “147,173 Shares in Abeona Therapeutics Inc. (ABEO) Purchased by EAM Investors LLC” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/147173-shares-in-abeona-therapeutics-inc-abeo-purchased-by-eam-investors-llc/1719832.html.
Shares of Abeona Therapeutics Inc. (ABEO) traded up $1.45 on Wednesday, hitting $16.15. 935,200 shares of the company were exchanged, compared to its average volume of 624,252. Abeona Therapeutics Inc. has a 12-month low of $4.05 and a 12-month high of $22.75.
Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings data on Wednesday, November 15th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.05. Abeona Therapeutics had a negative net margin of 2,946.58% and a negative return on equity of 27.69%. The firm had revenue of $0.22 million during the quarter, compared to analyst estimates of $0.22 million. research analysts expect that Abeona Therapeutics Inc. will post -0.7 EPS for the current fiscal year.
A number of equities research analysts have recently commented on the stock. Jefferies Group LLC reiterated a “buy” rating and issued a $28.00 target price on shares of Abeona Therapeutics in a research report on Wednesday. Maxim Group set a $17.00 target price on shares of Abeona Therapeutics and gave the company a “buy” rating in a research report on Wednesday, August 16th. Zacks Investment Research cut shares of Abeona Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, August 16th. HC Wainwright reiterated a “buy” rating and issued a $30.00 target price (up from $20.00) on shares of Abeona Therapeutics in a research report on Monday, October 16th. Finally, BidaskClub lowered shares of Abeona Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $25.30.
About Abeona Therapeutics
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
Want to see what other hedge funds are holding ABEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abeona Therapeutics Inc. (NASDAQ:ABEO).
Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.